Agilent Technologies Inc (NYSE:A) VP Rodney Gonsalves sold 6,825 shares of the business’s stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of $71.23, for a total transaction of $486,144.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Agilent Technologies Inc (NYSE:A) traded down $0.76 during mid-day trading on Wednesday, hitting $69.92. 1,866,288 shares of the stock traded hands, compared to its average volume of 2,920,000. Agilent Technologies Inc has a one year low of $51.96 and a one year high of $75.00. The firm has a market cap of $22,550.00, a price-to-earnings ratio of 31.21, a price-to-earnings-growth ratio of 2.36 and a beta of 1.30. The company has a quick ratio of 2.78, a current ratio of 3.23 and a debt-to-equity ratio of 0.40.
Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, February 14th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.08. Agilent Technologies had a net margin of 4.25% and a return on equity of 17.70%. The company had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same quarter in the previous year, the business earned $0.53 EPS. sell-side analysts predict that Agilent Technologies Inc will post 2.68 earnings per share for the current year.
Several hedge funds have recently made changes to their positions in A. BlackRock Inc. lifted its position in Agilent Technologies by 8.1% in the 4th quarter. BlackRock Inc. now owns 25,665,358 shares of the medical research company’s stock valued at $1,718,808,000 after acquiring an additional 1,912,186 shares in the last quarter. Renaissance Technologies LLC lifted its position in Agilent Technologies by 325.0% in the 4th quarter. Renaissance Technologies LLC now owns 2,370,200 shares of the medical research company’s stock valued at $158,732,000 after acquiring an additional 1,812,500 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Agilent Technologies by 145.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,726,929 shares of the medical research company’s stock valued at $115,652,000 after acquiring an additional 1,023,099 shares in the last quarter. TimesSquare Capital Management LLC bought a new stake in Agilent Technologies in the 3rd quarter valued at $58,550,000. Finally, Bank of Montreal Can lifted its position in Agilent Technologies by 187.3% in the 4th quarter. Bank of Montreal Can now owns 742,001 shares of the medical research company’s stock valued at $49,693,000 after acquiring an additional 483,721 shares in the last quarter.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.